Besides, inhibitors such as RM3 and UZH2 suppress tumor progression in melanoma, AML, and prostate cancer (PCa) by targeting the METTL3/METTL14 complex and reducing m6A modification levels [155, 156]. Here, METTL3 is linked to neoplasm.